Hints and tips:
...Mr Pigasse has advised some of France’s largest companies, including Carrefour, Sanofi, L’Oréal and Danone, and carved out a reputation advising on sovereign debt restructuring for Iraq, Ecuador, Argentina...
...A joint venture agreed with Sanofi in 2016 is aimed at improving diabetes care. These moves might not pay off....
...for Just Eat to £5bn as it seeks to clinch deal (FT) Former Guggenheim Partners president made bid for Premier League’s Chelsea (WSJ) IFF vies with Kerry in deal for DuPont nutrition business (BBG) Sanofi...
...Verily products like Onduo, a joint venture with Sanofi to create a diabetes management platform, might move closer to Google Health....
...Large corporations, including Unilever, Akzo Nobel and Sanofi, are all looking to dispose of multibillion units in the coming months and are all likely targets for private equity....
...For instance, Sanofi’s anti-clotting drug Plavix had 83 per cent of the market for drugs of its class in 2016, but that will fall to 60 per cent by 2020, as Chinese company Shenzhen Salubris makes gains,...
...We are cash rich . . . we have our Sanofi stake, we are absolutely financially very solid and we have what it takes to do anything.”...
...AkzoNobel has also put its specialty chemicals unit up for sale, and Sanofi is selling a drug unit. Both auctions have attracted interest from private equity....
...Sanofi, the French drugmaker, is seeking to sell its European generic drug business for about €3bn, drawing interest from a consortium formed by Cinven and Bain Capital....
...Last month, Sanofi the French pharmaceutical company said it would buy Bioverativ, a US biotech group focused on haemophilia treatments, for $11.6bn — a premium of about 64 per cent to where it was trading...
...It could add another €10bn by selling its stake in drugmaker Sanofi. Buying and cancelling the shares would add about 15 per cent to L’Oréal’s earnings per share, thinks RBC....
...I am delighted to welcome Yong-Jun to the Sanofi family....
...Since last Thursday more than $55bn have been spent by large companies, including Abbott Laboratories, AbbVie and Sanofi to secure growth generating assets....
...One of the latest signs of progress came in April 2016 when the World Health Organisation recommended that countries consider using Sanofi’s vaccine to combat dengue fever....
...A full auction has begun with GlaxoSmithKline, Sanofi and Galenica of Switzerland among the potential bidders, the people said....
...The 55-year-old German-Canadian said he had spent the time since leaving Sanofi identifying investment opportunities from his base in Massachusetts....
...GSK and Sanofi declined to comment. The pair are being advised by Lazard and Evercore respectively....
...Companies have lost hundreds of millions of dollars in failed trials, leading some such as Pfizer and Sanofi to drop out of the race. Others have doubled-down....
...Targets have included Home Depot, the DIY retailer, where Mr Whitworth eventually helped to force out chief executive Bob Nardelli, and the biotech firm Genzyme, which was eventually sold to Sanofi....
...Sanofi full-year earnings could be as much as 5 per cent beneath 2011 levels at constant exchange rates, as it posted fourth-quarter core earnings down 24 per cent to €1.19 a share....
...Royalty’s use of a contingent value right – a growing trend in conditional payments employed by others including Sanofi in its takeover of Genzyme – allows it to pay more based on the scale of future Tysabri...
...Then there are all the cash-rich, growth-poor pharma companies with a proven interest in diversification, from Sanofi to Bayer....
...Potential bidders for Bausch & Lomb include Abbot Group, Merck, Sanofi, Bayer, Pfizer, and GlaxoSmithKline. News of the potential sale was first reported by Bloomberg....
...Analysts have argued that they need to expand their scale in the diabetes sector, dominated by Eli Lilly, Sanofi and Novo Nordisk....
...He also has served on the board of Genzyme, the biotech company sold to Sanofi-Aventis this year for more than $20bn....
International Edition